List view / Grid view
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
29 September 2015 | By Victoria White
Advanced targeted therapies now account for 60% of the drugs under development for colorectal cancer...
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
CAMO Software, leaders in multivariate data analysis software, and Stat-Ease, Inc., a leading supplier of design of experiments (DOE) software and services, have released a software bundle for multivariate data analysis and design of experiments; The Unscrambler® X Design-Expert® Upgrade...
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
29 September 2015 | By Victoria White
Piramal Enterprises' Pharma Solutions division has set a target of becoming the market leader in ADCs contract commercialisation over the next five years...
29 September 2015 | By Victoria White
A pooled analysis from two Phase III studies showed a 38% reduction in risk of death in IPF patients who stayed on Esbriet treatment up to two years...
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
28 September 2015 | By Victoria White
Roche's study met its primary endpoint, showing treatment with ocrelizumab significantly reduced the progression of clinical disability...
28 September 2015 | By Victoria White
The results of the study, involving nearly 14,000 patients, may lead to new insights regarding the use of aspirin in gastrointestinal cancer...
28 September 2015 | By Victoria White
Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone...
28 September 2015 | By Victoria White
While VS-6063 had a generally well tolerated safety profile, there was not a sufficient level of efficacy to warrant continuation of the study...
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
28 September 2015 | By Victoria White
The combination also demonstrated significant health-related quality of life improvements, including overall health, physical and social functioning...
28 September 2015 | By Victoria White
The approval provides a new interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan...
